Clostridium difficile colitis:: Factors influencing treatment failure and relapse -: A prospective evaluation

被引:0
|
作者
Nair, S
Yadav, D
Corpuz, M
Pitchumoni, CS
机构
[1] Our Lady Mercy Univ Med Ctr, Div Gastroenterol & Infect Dis, Bronx, NY 10466 USA
[2] New York Med Coll, Bronx, NY USA
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 1998年 / 93卷 / 10期
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: The aim of this study was to identify patient related factors that may influence the treatment response and relapse following Clostridium difficile (C. difficile) colitis. Methods: A total of 36 patients with C. difficile colitis were followed for 3 months. Age, sex, place of residence, severity of infection, treatment, underlying medical condition, and treatment were compared in patients who failed to respond to treatment in 14 days and in patients who relapsed after a successful treatment. Student's t test and Fisher's exact test were used to compare the groups. A p value of <0.05 was considered significant. Results: A low serum albumin (p = 0.016) and continuation of systemic antibiotic treatment were found to be associated with refractoriness to treatment. Continuation or restarting of antibiotics after successful treatment increases the risk of relapse (p = 0.003). The age, sex place of residence, underlying medical condition, and type of precipitating antibiotics had no effect on the treatment response and relapse. The severity of colitis and the type of therapy (metronidazole vs vancomycin) did not influence the treatment response or relapse. Conclusion: Low serum albumin serves as a useful marker for patients who require prolonged treatment for C, difficile colitis. It is prudent to review the need for the continuation of systemic antibiotic treatment, as it adversely affects the treatment response and increases the risk of relapse. (Am J Gastroenterol 1998; 93:1873-1876. (C) 1998 by Am, Cell. of Gastroenterology)
引用
收藏
页码:1873 / 1876
页数:4
相关论文
共 50 条
  • [1] Predictive factors in clostridium difficile colitis for failure of medical and need for surgical treatment
    Gonzalez-Ruiz, Claudia
    Israelit, Shlomo
    Selvindoss, Paul
    Beart, Robert W.
    Vukasin, Petar
    Ault, Glenn
    Kaiser, Andreas M.
    GASTROENTEROLOGY, 2006, 130 (04) : A867 - A867
  • [2] Treatment Clostridium difficile colitis
    Le Berre, R.
    REVUE DE MEDECINE INTERNE, 2017, 38 : A35 - A39
  • [3] Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada
    Pépin, J
    Alary, ME
    Valiquette, L
    Raiche, E
    Ruel, J
    Fulop, K
    Godin, D
    Bourassa, C
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) : 1591 - 1597
  • [4] Clostridium difficile Colitis, Treatment and Management
    Hasty, Robert
    Barbato, Vincenzo
    Valdes, Pedro
    Sitler, Christopher
    CURRENT EMERGENCY AND HOSPITAL MEDICINE REPORTS, 2013, 1 (03): : 141 - 144
  • [5] TREATMENT OF CLOSTRIDIUM-DIFFICILE COLITIS
    BARTLETT, JG
    GASTROENTEROLOGY, 1985, 89 (05) : 1192 - 1195
  • [6] Nitazoxanide for the treatment of Clostridium difficile colitis
    Musher, Daniel M.
    Logan, Nancy
    Hamill, Richard J.
    DuPont, Herbert L.
    Lentnek, Arnold
    Gupta, Arvind
    Rossignol, Jean- Francois
    CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) : 421 - 427
  • [7] Clostridium difficile Colitis Prevention and Treatment
    Dinleyici, Meltem
    Vandenplas, Yvan
    PROBIOTICS AND CHILD GASTROINTESTINAL HEALTH: ADVANCES IN MICROBIOLOGY, INFECTIOUS DISEASES AND PUBLIC HEALTH, VOL 10, 2019, 1125 : 139 - 146
  • [8] THE TREATMENT OF CLOSTRIDIUM-DIFFICILE COLITIS
    CAPUTO, GM
    WEITEKAMP, MR
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (16): : 2088 - 2088
  • [9] Clostridium difficile Colitis, Treatment and Management
    Robert Hasty
    Vincenzo Barbato
    Pedro Valdes
    Christopher Sitler
    Current Emergency and Hospital Medicine Reports, 2013, 1 (3) : 141 - 144
  • [10] A 2ND RELAPSE OF CLOSTRIDIUM-DIFFICILE COLITIS
    RAMPLING, A
    SWAYNE, RL
    WARREN, RE
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 7 (02) : 212 - 212